Sodium fusidate in Gillain-Barre syndrome: A case report

F. Nicoletti, A. Nicoletti, S. Giuffrida, R. Di Marco, P. L. Meroni, K. Bendtzen, M. Lunetta

Research output: Contribution to journalArticlepeer-review


A patient with Guillain-Barre syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barre syndrome such as interleukin-2, interferon-γ, and tumor necrosis factor-α. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.

Original languageEnglish
Pages (from-to)266-268
Number of pages3
JournalJournal of Neurology, Neurosurgery and Psychiatry
Issue number2
Publication statusPublished - 1998


  • Autoimmunity
  • Cytokines
  • Fucidin
  • Guillian-Barre syndrome

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Psychiatry and Mental health


Dive into the research topics of 'Sodium fusidate in Gillain-Barre syndrome: A case report'. Together they form a unique fingerprint.

Cite this